Method for indicating the presence of neurodegenerative diseases using clinical biomarkers
Applications: Glycosphingolipid (GSL) biomarkers for Parkinson’s disease
A method of comparing ganglioside fingerprints from a patient sample, to diagnose disease or disorders such as Parkinson’s (PD) or Dementia. The invention also relates to classifying a subject into subgroups and so can be used stratifying patients for trials.
Features
Benefits
Parkinson’s plasma diagnostic.
Plasma changes in GSLs characteristic of PD can be identified and quantified.
Diagnostic test.
Could be used for determining risk, prognosis and stratification of patients for clinical trials of disease modifying therapies.
Glycosphingolipid fingerprint.
Change in GSL fingerprint characteristic of PD in multiple cohorts including prodromal patients to determine risk of progression to PD.